Tags : Roivant

M&A

Roivant Going Public Via MAAC SPAC Merger for ~$7.3B

Shots: Roivant signs a SPAC merger with MAAC for ~7.3B including $411M in cash in the MAAC trust account and $200M in PIPE stock at $10.00/share. The transaction is expected to deliver ~$611M to fund discovery and development programs and is expected to close in Q3’21 Roivant equity holders and Patient Square Capital have agreed […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 01 – 05, 2021)

Eli Lilly and Incyte Report Results of Olumiant (baricitinib) in P-III BRAVE-AA2 Study for Severe Alopecia Areata Published: Mar 5, 2021 | Tags: Eli Lilly and Incyte, Report, Results, Olumiant (baricitinib), P-III, BRAVE-AA2, Study, Severe, Alopecia Areata Takeda Reports NDA Submission to Import and Distribute Moderna’s mRNA-1273 in Japan Published: Mar 5, 2021 | Tags: […]Read More

M&A

Roivant to Acquire Silicon Therapeutics for ~$450M

Shots: Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for drug discovery The acquisition of Silicon will bolster Roivant’s targeted protein degradation platform that will be powered by VantAI’s ML techniques The integration of Silicon and VantAI will allow Roivant […]Read More

Top 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi’s agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology, lapscovery. The second position goes to the […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (September 09 – 13, 2019)

1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, E2609, Early Alzheimer’s Disease 2. GE Healthcare’s Critical Care Suite AI-Powered X-ray Device Receives FDA’s 510(k) Clearance to Identify Pneumothorax Published: Sept 12, 2019 | Tags: […]Read More

Biotech

Roivant Launches Cytovant Sciences to Collaborates with Medigene for the

Shots: Medigene to receive $10M upfront, $1B as development, regulatory, and commercial milestones & royalties on sales of four products in multiple indications. Cytovant to get exclusive development & commercialization rights for Medigene’s TCR therapy for NY-ESO-1 and Dendritic cell (DC) vaccine targeting WT-1 & PRAME in Greater China, South Korea, and Japan Cytovant and […]Read More